Statera Biopharma, Inc. Common Stock
STAB
STAB was delisted on the 11th of January, 2023.
15 hedge funds and large institutions have $454K invested in Statera Biopharma, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 2 closing their positions.
0.56% less ownership
Funds ownership: 4.55% → 3.99% (-0.56%)
6% less funds holding
Funds holding: 16 → 15 (-1)
20% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 5
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
82% less capital inflows, than outflows
Capital inflows: $23.5K | Capital outflows: $132K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$9.32K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$6.78K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$6.25K |
| 4 |
Bessemer Group
Woodbridge,
New Jersey
|
+$734 |
| 5 |
Ladenburg Thalmann Financial Services
Miami,
Florida
|
+$423 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$110K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$20.8K |
| 3 |
BlackRock
New York
|
-$442 |
| 4 |
Wells Fargo
San Francisco,
California
|
-$262 |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$178 |
STAB Hedge Fund Activity: Q4 2018 in Review
15 of the 4,506 institutional investors tracked by Wall St. Rank reported a position in Statera Biopharma, Inc. Common Stock (STAB) for Q4 2018, worth a combined $454K — down 56% from $1.03M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of STAB and 1 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $9.32K. The largest seller was Vanguard Group, cutting an estimated $110K.
- 15 institutional investors held Statera Biopharma, Inc. Common Stock (STAB) as of Q4 2018, down from 16 in Q3 2018.
- Funds reported $454K of Statera Biopharma, Inc. Common Stock stock for Q4 2018, down 56% quarter-over-quarter.
- 1 fund opened new Statera Biopharma, Inc. Common Stock positions in Q4 2018 and 2 closed out, a net change of -1 holder.
- The largest Statera Biopharma, Inc. Common Stock buyer in Q4 2018 was Renaissance Technologies, an estimated $9.32K added.
- The largest Statera Biopharma, Inc. Common Stock seller in Q4 2018 was Vanguard Group, an estimated $110K sold.
Based on aggregated 13F filings for Q4 2018.